Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Beijing
- Most recent report
- 6-K, filed Sep 2, 2026
- Filings on record
- 157 filings
- On EDGAR
- CIK 1962738
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer
Financials 8 of 71
- 6-K Report a foreign issuer made public elsewhere Sep 2, 2026
- 6-K Report a foreign issuer made public elsewhere Aug 14, 2026
- 6-K Report a foreign issuer made public elsewhere Aug 13, 2026
- 6-K Report a foreign issuer made public elsewhere Jul 15, 2026
- 6-K Report a foreign issuer made public elsewhere Jun 29, 2026
- 6-K Report a foreign issuer made public elsewhere Jun 2, 2026
- 20-F Annual report, foreign issuer May 15, 2026
- 6-K Report a foreign issuer made public elsewhere Apr 20, 2026
Prospectuses and Registrations 8 of 16
- 25-NSE Notice that a security was delisted Jun 23, 2026
- 424B5 Prospectus supplement for an offering Apr 1, 2025
- F-3 Dec 20, 2024
- F-3 Aug 16, 2024
- S-8 Registration statement for an employee plan Aug 14, 2024
- F-3 May 3, 2024
- S-8 POS Post-effective amendment to an employee plan registration May 23, 2023
- S-8 POS Post-effective amendment to an employee plan registration May 23, 2023
Ownership 8 of 41
- SCHEDULE 13D/A Large holder reported an active stake, amended May 18, 2026
- 3 Insider reported their initial holding Apr 23, 2026
- 3 Insider reported their initial holding Apr 20, 2026
- 3 Insider reported their initial holding Apr 16, 2026
- 3 Insider reported their initial holding Apr 13, 2026
- 3 Insider reported their initial holding Apr 7, 2026
- 3 Insider reported their initial holding Apr 3, 2026
- 3 Insider reported their initial holding Apr 3, 2026
Other 8 of 29
Everything here comes from CASI Pharmaceuticals, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.